Dr. Jeanne Drisko to BBC News:
"Patients are looking for safe and low-cost choices in their management of cancer. Intravenous vitamin C has that potential based on our basic science research and early clinical data."
Qi Chen, lead author of the new study wrote:
"Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies. We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C."...
Heidi Ledford at Nature wrote:
"[A]scorbate is processed by the body in different ways when administered orally versus intravenously."
"Oral doses [of vitamin C] act as antioxidants, protecting cells from damage caused by reactive compounds that contain oxygen. But vitamin C given intravenously can have the opposite effect by promoting the formation of one of those compounds: hydrogen peroxide. Cancer cells are particularly susceptible to damage by such reactive oxygen-containing compounds."
Comment Category Tags